Yazar "Demir, Gökhan" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial
    (Aves, 2020) Demir, Atakan; Mandel, Nil Molinas; Paydas, Semra; Demir, Gökhan; Er, Özlem; Turhal, Nazım Serdal; Bavbek, Sevil; Eralp, Yeşim; Saip, Pınar Mualla; Güler, Emine Nilüfer; Aydıner, Adnan; Uluç, Başak Oyan; Kılıçkap, Sadettin; Üskent, Necdet; Karadurmuş, Nuri; Kaplan, Mehmet Ali; Yanmaz, Mustafa Teoman; Demir, Hacer; Alan, Özkan; Korkmaz, Taner; Olgun, Polat; Uysal, Özlem Sönmez; Altundağ, Kadri; Gündüz, Seyda; Günaldı, Meral; Sarı, Murat; Beypınar, İsmail; Başaran, Gül
    Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2- metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2- patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.